Clinical trials: Cancer of Nasopharynx
Recurrent / Metastatic Nasopharyngeal Cancer
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts.
- Trial name
- NCT05198531
- Testing
- TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection
- Where
- 7 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Carcinoma
Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP chemotherapy combined with…
- Trial name
- NCT05417139
- Testing
- Immunotherapy+induction chemotherapy+radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy…
- Trial name
- NCT00592501
- Testing
- Proton/Photon Radiotherapy, Cisplatin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Nasopharyngeal Carcinoma, De-escalation Therapy
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06092957
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02633202
- Testing
- IMRT, Cisplatin
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Sun Yat-sen University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Nasopharyngeal Carcinoma
Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements
Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a qualified laboratory in Southern China, the highest endemic…
- Trial name
- NCT05037357
- Testing
- Plasma EBV DNA qPCR test
- Where
- China
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or…
- Trial name
- NCT00006471
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04398056
- Testing
- Chemotherapy plus radiotherapy and Toripalimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
This phase II trial studies how well durvalumab and epacadostat work in treating patients with Epstein-Barr virus positive nasopharyngeal cancer that cannot be removed by surgery (unresectable), has come back (recurrent), or has…
- Conditions
- Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma
- Trial name
- NCT04231864
- Testing
- Durvalumab, Epacadostat
- Sponsor
- Alain Algazi
Nasopharyngeal Carcinoma (NPC)
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma.
- Trial name
- NCT06611150
- Testing
- Nab-paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
We aim, in this study, to examine whether reduction of FLT PET derived SUV before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal…
- Trial name
- NCT03689556
- Testing
- FLT PET/CT
- Volunteers
- 40 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma
Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma(NPC).
- Trial name
- NCT04745741
- Testing
- IB-positive group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma
- Trial name
- NCT03708822
- Testing
- Docetaxel and Cisplatin and Nimotuzumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Molecular Mechanism of Nasopharyngeal Carcinoma
EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses.
- Trial name
- NCT00155181
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Stage II, III, Nasopharyngeal Squamous Cell Carcinoma
Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma
The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.
- Conditions
- Stage II, III, Nasopharyngeal Squamous Cell Carcinoma, Induction Chemotheray, Concurrent Chemoradiotherapy
- Trial name
- NCT03908372
- Testing
- Docetaxel, Cisplatin, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Malignant Neoplasm of Other Specified Site of Nasopharynx
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified…
- Trial name
- NCT02604472
- Testing
- CCRT, IC+CCRT
- Volunteers
- 12,206 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms
Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma
Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC).
- Conditions
- Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms, Radiosensitivity
- Trial name
- NCT02481089
- Testing
- validation group
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.